# A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)

> clinical trial · VERIFIED · 2026-08-13

Status: ACTIVE_NOT_RECRUITING · Sponsor: Merck Sharp & Dohme LLC · Condition: Essential Thrombocythemia

- Company: Merck Sharp & Dohme LLC
- Sector: therapeutics
- Primary source: https://clinicaltrials.gov/study/NCT06079879

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.